Lin Fa Wang

Duke-NUS Medical School - Programme in Emerging Infectious Diseases

SCHOLARLY PAPERS

5

DOWNLOADS

497

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (5)

1.

Antibody Response of Heterologous vs Homologous mRNA Vaccine Boosters Against the SARS-CoV-2 Omicron Variant: Interim Results from the PRIBIVAC Study, A Randomized Clinical Trial

Number of pages: 35 Posted: 16 Mar 2022
National Centre for Infectious Diseases, Duke NUS Medical School, National Centre for Infectious Diseases, National Centre for Infectious Diseases, Agency for Science, Technology and Research (A*STAR) - A*STAR Infectious Diseases Labs, University of Liverpool, University of Liverpool, Duke-NUS Medical School, National Centre for Infectious Diseases, National Centre for Infectious Diseases, National Centre for Infectious Diseases, Singapore, National Centre for Infectious Diseases, Singapore, National Centre for Infectious Diseases, National Centre for Infectious Diseases, National Centre for Infectious Diseases, National Centre for Infectious Diseases, National Centre for Infectious Diseases, Duke-NUS Medical School, University of Liverpool, Agency for Science, Technology and Research (A*STAR) - A*STAR Infectious Diseases Labs, National University of Singapore (NUS), National Centre for Infectious Diseases, Agency for Science, Technology and Research (A*STAR) - A*STAR Infectious Diseases Labs, Nanyang Technological University (NTU) - Lee Kong Chian School of Medicine, Duke-NUS Medical School - Programme in Emerging Infectious Diseases and National Centre for Infectious Diseases, Singapore
Downloads 200 (259,968)
Citation 5

Abstract:

Loading...

COVID-19 vaccine booster, humoral immunity, omicron, live virus neutralization

2.

Pathogen Genomic Surveillance in Asia: A Multi-Country Assessment

Number of pages: 28 Posted: 28 Jul 2023
National University of Singapore (NUS) - Programme in Health Services and Systems Research, National University of Singapore (NUS) - Centre for Outbreak Preparedness, National University of Singapore (NUS) - Centre for Outbreak Preparedness, National University of Singapore (NUS) - Centre for Outbreak Preparedness, National University of Singapore (NUS) - Centre for Outbreak Preparedness, National University of Singapore (NUS) - Duke-NUS Medical School, National University of Singapore (NUS) - Centre for Outbreak Preparedness, National University of Singapore (NUS) - Centre for Outbreak Preparedness, National University of Singapore (NUS) - Centre for Outbreak Preparedness, The SingHealth Duke-NUS Global Health Institute (SDGHI), Agency for Science, Technology and Research (A*STAR) - Bioinformatics Institute, Duke-NUS Medical School, Duke-NUS Medical School - Programme in Emerging Infectious Diseases, The SingHealth Duke-NUS Global Health Institute (SDGHI) and Independent
Downloads 115 (416,388)

Abstract:

Loading...

infectious disease surveillance, genomics, whole genome sequencing, high throughput sequencing, cross-sectional analysis, emergency preparedness, pandemic preparedness, outbreak preparedness, Asia, South Asia, Southeast Asia, ASEAN

3.

Interim Results from a Phase I Trial of Novel SARS-CoV-2 Beta Variant Receptor-Binding Domain Recombinant Protein and mRNA Vaccines as a 4 th Dose Booster

Number of pages: 43 Posted: 29 Jun 2023
University of Melbourne - Peter Doherty Institute for Infection and Immunity, The University of Melbourne, The University of Melbourne, University of Melbourne - Departments of Medicine and Infectious Diseases at the Doherty Institute, University of Melbourne - Department of Microbiology and Immunology, University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne - Peter Doherty Institute for Infection and Immunity, The University of Melbourne, The University of Melbourne, The University of Melbourne, Flinders University, The University of Melbourne, The University of Melbourne, The University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Peter Doherty Institute for Infection and Immunity, The University of Melbourne, University of Melbourne - Department of Microbiology and Immunology, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), The University of Melbourne - Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, The University of Melbourne, The University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), The University of Melbourne, University of Melbourne - Royal Melbourne Hospital, University of Melbourne - Centre for Epidemiology and Biostatistics, The University of Melbourne, Monash University - Monash Institute of Pharmaceutical Sciences, Monash University - Monash Institute of Pharmaceutical Sciences, Monash University - Monash Institute of Pharmaceutical Sciences, SingHealth Duke-NUS Global Health Institute, University of Melbourne - Department of Microbiology and Immunology (DMI), Flinders University, Duke-NUS Medical School - Programme in Emerging Infectious Diseases, Monash University - Monash Institute of Pharmaceutical Sciences, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Centre for Epidemiology and Biostatistics, Monash University - Monash Institute of Pharmaceutical Sciences and University of Melbourne - Department of Microbiology and Immunology (DMI)
Downloads 91 (479,875)

Abstract:

Loading...

SARS-CoV-2, vaccine, receptor binding domain, recombinant protein, mRNA, beta variant, phase I trial.

4.

Contrasting SARS-CoV-2 Epidemics in Singapore: Cohort Studies in Migrant Workers and the General Population

Number of pages: 15 Posted: 15 Apr 2021
National University of Singapore (NUS) - Saw Swee Hock School of Public Health, Duke-NUS Medical School - Programme in Emerging Infectious Diseases, National University of Singapore (NUS) - Saw Swee Hock School of Public Health, National University of Singapore (NUS) - Saw Swee Hock School of Public Health, National University of Singapore (NUS) - Saw Swee Hock School of Public Health, National University of Singapore (NUS) - Saw Swee Hock School of Public Health, National University of Singapore (NUS) - Saw Swee Hock School of Public Health, National University of Singapore (NUS) - Saw Swee Hock School of Public Health, National University of Singapore (NUS) - Saw Swee Hock School of Public Health, National University Health System, Alexandra Hospital - Infectious Diseases, Duke-NUS Medical School - Programme in Emerging Infectious Diseases and National University of Singapore (NUS) - Saw Swee Hock School of Public Health
Downloads 55 (631,579)

Abstract:

Loading...

5.

The Impact of SARS-CoV-2 Vaccination and Infection on Neutralising Antibodies: A Nation-Wide Cross-Sectional Analysis

Number of pages: 30 Posted: 07 Dec 2022
Centre Scientifique de Monaco, Aix-Marseille University - Aix Marseille Institute of Public Health ISSPAM, National University of Singapore (NUS) - Program in Emerging Infectious Diseases, Centre Scientifique de Monaco, Centre Scientifique de Monaco, Centre Scientifique de Monaco, Centre Scientifique de Monaco, Centre Scientifique de Monaco, Government of the United Kingdom - Vaccines (Research and Development), GenScript Biotech, Duke-NUS Medical School - Programme in Emerging Infectious Diseases and Direction de l’Action Sanitaire
Downloads 36 (749,899)

Abstract:

Loading...

SARS-CoV-2, neutralizing antibodies, vaccination, COVID-19, hybrid immunity